Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Summit Therapeutics Inc.

35 indications, side-by-side phase, drug & LoA

$14.01

+1.11 (+8.49%)

B 64Pipeline Score Overvalued Biotech · Commercial
Market Cap
12.90 B
EPS
-1.60
P/E Ratio
-
Value Trade
65.15 M
SEC Financials
Q1 2026

  • Dilution Risk

    25%

  • R&D Expenses

    132.62 M

  • Operating CF

    -122.29 M

  • Total Assets

    647.86 M

  • Total Liabilities

    101.92 M

  • Equity

    545.93 M

  • D/E Ratio

    12,345

-6.52 %
Week
-37.61 %
1 Month
5.99 %
3 Month
1.34 %
6 Month
117.25 %
5 Year
65.87 %
All Time
Cash Data
Stable

  • Cash Position

    598.73 M

  • Monthly Burn

    40.76 M

  • Runway

    13.4 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    Apr 30, 2026
Overview
Volume
9.88 M
52 Week Range
13.83 - 30.98
% held by Insiders
82.68 %
% held by Institutions
15.53 %
Enterprise Value
12.32 B
Total Shares
777.87 M
Short %
26.85 %
Float Shares
134.57 M
Company Description
HQ: 601 BRICKELL KEY DRIVE, MIAMI,...
Employees:265
https://www.smmttx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA Date example
ivonescimab EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer post-tyrosine kinase inhibitor (TKI) therapy
PDUFA
—
Biologics
Oncology
ivonescimab EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer post-tyrosine kinase inhibitor (TKI) therapy
PDUFA
—
Biologics
Oncology
ivonescimab EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer post-tyrosine kinase inhibitor (TKI) therapy
PDUFA
—
Biologics
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
B64
Pipeline Score
$6.1B
Pipeline Value
Overvalued
Valuation Signal
9
Drugs Scored
0.5x
rNPV / MCap
Top 90%
Mid Cap
(rank 91 of 905)
Percentile Rank
Summit Therapeutics Inc. holds a solid B-grade pipeline (64/100), with $7.2B risk-adjusted pipeline value, led by Ivonescimab in Non-Small Cell Lung Cancer (Phase 3), across $185B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Ivonescimab
Small molecule		Non-Small Cell Lung CancerPhase 3NCT0753543746% $3.1B RECRUITING 2,499 - -Apr 1, 2028MODERATE_RISKLOW
May 24, 2026
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Ivonescimab
EGFRm NSCLC,Advanced NSCLC,Squamous NSCLC,Locally advanced or metastatic NSCLC
Phase 3
2025-08-12
Ivonescimab
EGFRm NSCLC,Advanced NSCLC,Squamous NSCLC,Locally advanced or metastatic NSCLC
Phase 3
2025-08-12
Ivonescimab
EGFRm NSCLC,Advanced NSCLC,Squamous NSCLC,Locally advanced or metastatic NSCLC
Phase 3
2025-08-12
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in SMMT
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
SMMT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SMMT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SMMT
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
SMMT Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
SMMT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-020 0.00 0 0 - - - - - -
2026-07-020 0.00 0 0 - - - - - -
2026-07-020 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Summit Therapeutics Inc. (SMMT) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How SMMT ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
PTSD #4 of 9 PHASE 2 Hyperbaric Oxygen Therapy
CMPS MASI ADPT
—0 CONTENDER
Traumatic Brain Injury #5 of 7 PHASE 2 Hyperbaric Oxygen Therapy
OGEN NVO SUPN
$4.0B 0 CONTENDER
Colorectal Cancer #8 of 82 PHASE 3 Drug: Ivonescimab + Drug: Bevacizumab
ABBV BMY MRK
$7.68B 0.91 CONTENDER
Lung Cancer #12 of 79 PHASE 3 AK112
MRK GILD AMGN
$28.1B 0.89 CONTENDER
Non-Small Cell Lung Cancer #15 of 88 PHASE 3 Ivonescimab + Pembrolizumab
MRK AMGN AZN
$28.1B 0.89 CONTENDER
Cholangiocarcinoma #18 of 24 PHASE 2 Ivonescimab + FOLFOX regimen
AZN JAZZ LLY
$0.62B 0 FOLLOWER
Head and Neck Cancer #19 of 63 PHASE 3 Ivonescimab /kg + Ligufalimab + Pembrolizumab
AZN GSK MRK
$10.2B 0 FOLLOWER
Gastric Cancer #35 of 49 PHASE 2 Ivonescimab + FOLFOX regimen + Irinotecan + Paclitaxel
AZN ONC JAZZ
$6.74B 0 FOLLOWER